Persistent epigenetic memory impedes rescue of the telomeric phenotype in human ICF iPSCs following DNMT3B correction.
Shir ToubianaMiriam GagliardiMariarosaria PapaRoberta MancoMaty TzukermanMaria R MatarazzoSara SeligPublished in: eLife (2019)
DNA methyltransferase 3B (DNMT3B) is the major DNMT that methylates mammalian genomes during early development. Mutations in human DNMT3B disrupt genome-wide DNA methylation patterns and result in ICF syndrome type 1 (ICF1). To study whether normal DNA methylation patterns may be restored in ICF1 cells, we corrected DNMT3B mutations in induced pluripotent stem cells from ICF1 patients. Focusing on repetitive regions, we show that in contrast to pericentromeric repeats, which reacquire normal methylation, the majority of subtelomeres acquire only partial DNA methylation and, accordingly, the ICF1 telomeric phenotype persists. Subtelomeres resistant to de novo methylation were characterized by abnormally high H3K4 trimethylation (H3K4me3), and short-term reduction of H3K4me3 by pharmacological intervention partially restored subtelomeric DNA methylation. These findings demonstrate that the abnormal epigenetic landscape established in ICF1 cells restricts the recruitment of DNMT3B, and suggest that rescue of epigenetic diseases with genome-wide disruptions will demand further manipulation beyond mutation correction.
Keyphrases
- dna methylation
- genome wide
- induced pluripotent stem cells
- gene expression
- induced apoptosis
- endothelial cells
- copy number
- end stage renal disease
- cell cycle arrest
- randomized controlled trial
- newly diagnosed
- peritoneal dialysis
- magnetic resonance
- signaling pathway
- chronic kidney disease
- prognostic factors
- endoplasmic reticulum stress
- dna damage response
- high frequency
- dna damage
- magnetic resonance imaging
- working memory
- pluripotent stem cells
- circulating tumor
- single cell
- contrast enhanced
- circulating tumor cells